Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 198.27M P/E - EPS this Y 25.90% Ern Qtrly Grth -
Income -113.87M Forward P/E -1.63 EPS next Y -5.00% 50D Avg Chg -11.00%
Sales 60.28M PEG -2.62 EPS past 5Y - 200D Avg Chg -38.00%
Dividend N/A Price/Book 1.74 EPS next 5Y 1.00% 52W High Chg -67.00%
Recommedations 2.40 Quick Ratio 2.66 Shares Outstanding 255.56M 52W Low Chg 1.00%
Insider Own 0.20% ROA -28.22% Shares Float 734.09M Beta 2.38
Inst Own 67.52% ROE -187.61% Shares Shorted/Prior 3.20M/2.80M Price 0.88
Gross Margin -109.87% Profit Margin -188.90% Avg. Volume 892,806 Target Price 3.50
Oper. Margin -21,582.68% Earnings Date Mar 4 Volume 380,104 Change -3.06%
About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics plc News
04/15/24 Adaptimmune (ADAP) Down on End of Collaboration With Roche
04/12/24 Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
04/12/24 Roche, Adaptimmune part ways on cell therapy research
03/27/24 Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
03/08/24 Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/07/24 Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
03/07/24 Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
03/06/24 Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
02/27/24 Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
02/21/24 Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
02/16/24 15 Top Performing European Stocks So Far in 2024
02/13/24 Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
01/31/24 Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
01/30/24 Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
05:23 AM Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
01/16/24 Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
01/04/24 Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
12/07/23 Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
12/06/23 Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
11/30/23 Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
ADAP Chatroom

User Image MK_bio Posted - 2 hours ago

$ADAP My 2 cents... Wait until after investor day, AGM and Q1'24 earnings to buy the dip and ride the run-up to PDUFA You'll be taking a chance if you place your chips before 🤷‍♂️

User Image slick3333 Posted - 5 hours ago

$ADAP dang forgot about investors meeting tomorrow ….not feeling too confident and sad to see us hit day 1 below a buck

User Image Runmaster83 Posted - 6 hours ago

$ADAP

User Image Erminiottone Posted - 7 hours ago

$ADAP

User Image JustEk33 Posted - 7 hours ago

$ADAP really solid price action before the clown speaks tomorrow and heading into PDUFA. Who else thinks that will fail too ?

User Image BioCrEq Posted - 7 hours ago

$ADAP low volume manipulation by WS crooks!

User Image Moneybrock Posted - 7 hours ago

$ADAP looks like I'll be bag holding for a bit

User Image DoctrBenway Posted - 9 hours ago

@Whtmtn @dhovekamp42 @BioCrEq Thanks for the clarification. I am very excited about PRAME and the large number of melanoma patients that would be addressable -- the company will report on this in its own time. Biotech, especially when well-executed is slow business. Better to wait to announce something positive than just the expenditures and (probably incremental) progress that are being made. These should be covered in quarterlies and I will try to elucidate when such data are present. We're all frustrated, I'm sure. $ADAP

User Image DoctrBenway Posted - 9 hours ago

@BioCrEq @Whtmtn @dhovekamp42 All the above having been stated, Dieter is not the problem with this company. He has provided good information, albeit not the info some would want. The stock needs more people who can concentrate on the positives of the company as he does. No one is buying or selling this stock based on his opinions. We all did our own DD (at least I hope we all did). $ADAP

User Image Bionco Posted - 10 hours ago

$ADAP though termination of the agreement is a brutal deal, it isn't so bad Adap received (will receive) up to 240m $ cash in total(150m$ upfront payment plus 90m$ for 3 years corporation). The best way for ADAP is to find a partner to commercialize its afami-cel after its approval and to shift its priority to Uza-cel.

User Image tranq19 Posted - 10 hours ago

$ADAP short covering this afternoon?

User Image GinoGino Posted - 23 hours ago

$ADAP Good to hear from you, buddy, and I always appreciate your very positive outlook! Let's start with the meager market cap of $270 mil. You and others here seem to be treating this company as if it had a multibillion-dollar market cap. I understand that the market is pricing in the worst-case scenario, in line with what you have outlined, but I see things differently. I'm not going to repeat what I've said before and will wait for the coming months to see how things turn out. Expected FDA news in early August with commercialization likely to follow immediately. There are three scenarios here: a multi-bag return on our investment (in line with my optimism), a $4-$5 range after approval (which the majority seem to expect), and a disaster where the price stays in this range or even goes lower (as you and other bears are predicting). Let's see which of these scenarios plays out by year-end!

User Image dhovekamp42 Posted - 1 day ago

$ADAP all investors should look to get prepared for action to be taken on voting at the Adaptimmune AGM planned for May 14th 2024 https://ir.stockpr.com/adaptimmune/sec-filings-email/content/0001104659-24-041530/tm242701-d2_pre14a.htm

User Image Runmaster83 Posted - 1 day ago

$ADAP So bearish!

User Image JJmcnasty Posted - 1 day ago

$ADAP they should be giving free blow jobs to anyone who has been a long term investor in this company on investor day

User Image Erminiottone Posted - 1 day ago

$ADAP collapse imminent

User Image BioCrEq Posted - 1 day ago

$ADAP what will happen when Ad talks about Sarcoma franchise again on Thursday and doesn’t focus on pipeline?

User Image Biorun Posted - 1 day ago

$ADAP not adding myself but looks good to add below $1 with stop loss at $.958

User Image JustEk33 Posted - 1 day ago

$ADAP ecor down a solid 40%+ from their investment in just a month. Welcome to the party from hell!

User Image YouVSYou Posted - 1 day ago

$ADAP

User Image CliffordCapital Posted - 1 day ago

$MIST MM loading.. check trade log. $HUMA good news today!! $ADAP PAAAIINN… but tables will turn once we get closer to august!

User Image BioCrEq Posted - 1 day ago

$ADAP sharp vertical drops are clearly algo driven. Who the f*** is controlling this stock?

User Image Apr4609 Posted - 1 day ago

$ADAP 1$ seems like the place to add given that fda decision is 100 days away

User Image Erminiottone Posted - 1 day ago

$ADAP

User Image YoYoHoneySingh Posted - 1 day ago

$ADAP thank you for discount loaded more today at $1.08

User Image Longroader Posted - 1 day ago

$ADAP XBI today down 2%, ytd -4.3%, rocky days. Below 1s maybe good chance to add.

User Image GinoGino Posted - 2 days ago

$ADAP overall market sentiment stinks, sector stinks, geopolitics f*cked up and bad news—which actually is not that bad—adds salt to the wound. But the more important question I have is what the f*ck investors are expecting considering the shit market cap? FDA approval around the corner and commercialization likely to follow fast, bringing in 100s of millions annually to support the company’s robust pipeline. To me it way seems overdone and a no-brainer investment.

User Image precise Posted - 2 days ago

$ADAP There you go, RSI 30, start nibbling

User Image dhovekamp42 Posted - 2 days ago

@mikiass1 interesting confusion about the relation of Afami-cel BLA and Genentech partnership - both have no structural or other overlap. Afami-cel is and always was wholly owned / developed by $ADAP and Roche brought its own TCR targets to the deal about future use of Adaptimmunes allogeneic cells within Genentech

User Image Runmaster83 Posted - 2 days ago

$ADAP Pure Manipulation…..Are you scared??? If not, get ready to buy more! 💰

Analyst Ratings
Barclays Underweight Aug 10, 23
EF Hutton Buy Aug 10, 23
EF Hutton Buy Jun 5, 23
EF Hutton Buy Jun 2, 23
EF Hutton Buy May 26, 23
EF Hutton Buy Apr 17, 23
EF Hutton Buy Apr 11, 23
EF Hutton Buy Mar 6, 23
EF Hutton Buy Jan 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 16 Sell 0.73 39,384 28,750 44,848 01/17/24
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 16 Sell 0.71 20,563 14,600 19,257 01/17/24
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 16 Sell 0.71 22,795 16,184 19,015 01/17/24
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 16 Sell 0.71 23,589 16,748 20,201 01/17/24
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 0.85 11,808 10,037 11,841 01/12/24
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 0.85 9,229 7,845 7,874 01/12/24
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 0.85 29,202 24,822 26,388 01/12/24
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 0.85 9,229 7,845 7,874 01/12/24
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 0.78 2,403 1,874 3,449 09/01/23
Menzel Garry E Director Director Jul 10 Sell 0.9108 47,702 43,447 75,056 07/10/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jun 27 Sell 0.92 2,333 2,146 3,519 06/27/23
Piccina Cintia Chief Commercial Off.. Chief Commercial Officer Jan 31 Sell 1.8696 11,890 22,230 19,535 01/31/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 17 Sell 1.858 4,440 8,250 7,264 01/17/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 17 Sell 1.858 4,440 8,250 7,264 01/17/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 17 Sell 1.858 2,159 4,011 3,491 01/17/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 17 Sell 1.858 10,057 18,686 13,351 01/17/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 1.73 8,816 15,252 8,121 01/12/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 1.73 8,816 15,252 8,121 01/12/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 1.73 11,292 19,535 12,191 01/12/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 1.73 31,805 55,023 24,882 01/12/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 04 Sell 1.694 3,584 6,071 5,781 01/04/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 04 Sell 1.6940 1,100 1,863 1,725 01/04/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 04 Sell 1.6940 876 1,484 1,361 01/04/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 04 Sell 1.6940 5,073 8,594 6,631 01/04/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 1.9689 2,536 4,993 3,316 09/01/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Aug 01 Sell 1.7735 2,983 5,290 4,829 08/01/22
Piccina Cintia Chief Commercial Off.. Chief Commercial Officer Aug 01 Sell 1.7735 21,040 37,314 34,824 08/01/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jul 05 Sell 1.6781 1,973 3,311 3,104 07/05/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jun 27 Sell 1.63 2,562 4,176 3,290 06/27/22
Wood Gavin Chief Financial Offi.. Chief Financial Officer May 20 Buy 0.2904 39,000 11,326 96,000 05/23/22
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 18 Sell 3.1918 4,368 13,942 7,336 01/18/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 18 Sell 3.1918 4,368 13,942 7,336 01/18/22
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 18 Sell 3.1918 2,121 6,770 3,529 01/18/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 18 Sell 3.1918 11,096 35,416 12,312 01/18/22
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 3.55 6,018 21,364 3,754 01/13/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 3.55 4,846 17,203 1,749 01/13/22
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 3.55 4,624 16,415 1,383 01/13/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 3.55 17,408 61,798 3,356 01/13/22